Phase I/IIa trial of 7HP349 in patients with PD-1 checkpoint inhibitor resistant solid tumors
Latest Information Update: 25 May 2023
At a glance
- Drugs Alintegmod (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors 7 Hills Pharma
- 22 May 2023 According to 7 Hill Pharma media release, the company as been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 into this trial.
- 09 Nov 2020 According to 7 Hill Pharma media release, company expects to move into this trial in next year (2021).
- 24 Sep 2020 New trial record